title: Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication.
abstract: As Helicobacter pylori is a first-class carcinogen, eradication of the infection would be expected to be a beneficial measure for the (primary) prevention of gastric cancer. Given the natural history of gastric cancer, it is plausible that eradication before gastric atrophy sets in offers the best chance for cancer risk reduction. The beneficial effects of eradication may, nevertheless, still be achievable in more advanced disease. The reversibility of inflammatory lesions has been supported by undeniable evidence; the regression of mucosal atrophy/metaplasia has also been confirmed by several recent histologic studies.
authors: Surgical Pathology & Cytopathology Unit, Department of Medicine - DIMED, University of Padova, Via Aristide Gabelli, 61, Padova 35121, Italy. Electronic address: massimo.rugge@unipd.it.
authors: Massimo
authors: M
authors: Rugge
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents
keywords: Atrophic gastritis; Gastric cancer prevention; Gastric cancer risk; H pylori; OLGA staging; Pepsinogens